Biocept Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BIOC Nasdaq 2834 https://biocept.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biocept Inc

Biocept to Present at the LD Micro Main Event on October 13 - Oct 6th, 2021 12:00 pm
Biocept: A New Diagnostic Approach to Improve the Lives of Cancer Patients - Sep 29th, 2021 5:28 pm
Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic - Sep 22nd, 2021 12:17 pm
Biocept Invites You to Join Us at the Benzinga Healthcare Small Cap Conference - Sep 22nd, 2021 11:00 am
Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations - Sep 21st, 2021 12:17 pm
Biocept to Present at Four Virtual Investor Conferences in September - Sep 7th, 2021 12:00 pm
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 1st, 2021 12:00 am
This Analyst Just Made A Massive Upgrade To Their Biocept, Inc. (NASDAQ:BIOC) Earnings Forecasts - Aug 22nd, 2021 12:17 pm
Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay - Aug 19th, 2021 3:37 pm
Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer - Aug 19th, 2021 12:34 pm
Biocept Stock Drops Despite Clocking Q2 Sales Of $12M - Aug 17th, 2021 3:22 pm
Biocept Reports Second Quarter 2021 Financial Results - Aug 16th, 2021 8:05 pm
Biocept to Report Second Quarter 2021 Financial Results and Host Investor Conference Call on August 16, 2021 - Aug 9th, 2021 12:00 pm
Biocept Names David Karlander as Senior Vice President of Commercial Operations - Aug 3rd, 2021 12:17 pm
Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells - Jul 21st, 2021 12:17 pm
Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman - Jul 20th, 2021 12:17 pm
Biocept to Participate in Two July Investment Conferences - Jul 19th, 2021 12:00 pm
Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers - Jul 6th, 2021 12:27 pm
Biocept Joins the Russell Microcap® Index - Jun 28th, 2021 12:05 pm
Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer - Jun 22nd, 2021 12:17 pm